CAS 138660-97-6
:Tuvirumab
Description:
Tuvirumab, with the CAS number 138660-97-6, is a monoclonal antibody that has been developed for therapeutic use, particularly in the context of viral infections. It is designed to target specific viral antigens, thereby neutralizing the virus and preventing its replication. The structure of Tuvirumab consists of a variable region that binds to the viral target and a constant region that mediates immune responses. This antibody exhibits high specificity and affinity for its target, which is crucial for its efficacy in treatment. Tuvirumab is typically administered via injection and may be used in various clinical settings, including acute viral infections. Its pharmacokinetics involve distribution throughout the body, with a half-life that allows for sustained therapeutic effects. As with many monoclonal antibodies, potential side effects may include infusion reactions and immune-related responses. Ongoing research continues to evaluate its effectiveness and safety profile in different patient populations.
Formula:Unspecified
Synonyms:- Tuvirumab
- SDZ-OST 577
- Immunoglobulin G1, anti-(hepatitis B virus surface antigen) (human monoclonal PE1-1 γ1-chain), disulfide with human monoclonal PE1-1 λ-chain, dimer
- Immunoglobulin G 1 (human monoclonal PE1-1 anti-hepatitis B virus surface antigen), disulfide with human monoclonal PE1-1 λ-chain, dimer
- PE 1-1
Sort by
The purity filter is not visible because current products do not have associated purity data for filtering.
Found 2 products.
Tuvirumab
CAS:Tuvirumab, a human IgG1 monoclonal antibody, targets HBsAg with high affinity (K=3.6 nM) for chronic hepatitis B research.Color and Shape:Liquid
